Quarterly Report • May 7, 2025
Quarterly Report
Open in ViewerOpens in native device viewer
MLP SAĞLIK HİZMETLERİ A.Ş. AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED 1 JANUARY- MARCH 31, 2025
| INDEX | PAGE | |
|---|---|---|
| CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION | 1-2 | |
| CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSS | ||
| AND OTHER COMPREHENSIVE INCOME | 3 | |
| CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY | 4 | |
| CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS | 5 | |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS | 6-41 | |
| NOTE 1 | ORGANIZATION AND OPERATIONS OF THE GROUP | |
| NOTE 2 | BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS | |
| NOTE 3 | RELATED PARTY DISCLOSURES | |
| NOTE 4 | CASH AND CASH EQUIVALENTS | |
| NOTE 5 | FINANCIAL INSTRUMENTS | |
| NOTE 6 | TRADE RECEIVABLES AND PAYABLES | |
| NOTE 7 | OTHER RECEIVABLES AND PAYABLES | |
| NOTE 8 | INVENTORIES | |
| NOTE 9 | PREPAID EXPENSES AND DEFERRED INCOME | |
| NOTE 10 | PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS | |
| NOTE 11 | RIGHT OF USE ASSETS | |
| NOTE 12 | PAYABLES FOR EMPLOYEE BENEFITS | |
| NOTE 13 | OTHER ASSETS AND LIABILITIES | |
| NOTE 14 | PROVISIONS | |
| NOTE 15 | COMMITMENTS | |
| NOTE 16 | SHARE CAPITAL/OTHER RESERVES | |
| NOTE 17 | REVENUE | |
| NOTE 18 | OPERATING EXPENSES | |
| NOTE 19 | OTHER INCOME AND EXPENSE FROM OPERATING ACTIVITIES | |
| NOTE 20 | INCOME AND EXPENSES FROM INVESTING ACTIVITIES | |
| NOTE 21 | FINANCE EXPENSES | |
| NOTE 22 | EXPLANATION ON NET MONETARY POSITION GAINS/ (LOSES) | |
| NOTE 23 | TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED) | |
| NOTE 24 | EARNINGS PER SHARE | |
| NOTE 25 | FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES | |
| NOTE 26 | EVENTS AFTER THE REPORTING PERIOD | |
APPENDIX I EARNINGS BEFORE INTEREST TAXES DEPRECIATION AND AMORTISATION ("EBITDA") 42
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Unaudited | Audited | ||
|---|---|---|---|
| Notes | 31 March 2025 | 31 December 2024 | |
| ASSETS | |||
| Current Assets: | 13,815,147 | 12,313,667 | |
| Cash and cash equivalents | 4 | 3,614,754 | 3,002,094 |
| Trade receivables | 6 | 7,657,942 | 6,699,571 |
| - Due from related parties | 3,6 | 35,222 | 32,548 |
| - Trade receivables from third parties | 7,622,720 | 6,667,023 | |
| Other receivables | 7 | 422,881 | 392,784 |
| - Due from related parties | 3,7 | 319,998 | 301,050 |
| - Other receivables from third parties | 102,883 | 91,734 | |
| Inventories | 8 | 902,169 | 1,104,691 |
| Prepaid expenses | 9 | 816,869 | 688,978 |
| Other current assets | 13 | 400,532 | 425,549 |
| Non-current Assets: | 42,352,857 | 39,736,545 | |
| Trade receivables | 6 | 1,053 | 1,159 |
| Other receivables | 7 | 986,086 | 820,596 |
| Property plant and equipment | 10 | 8,786,041 | 8,543,071 |
| Intangible assets | 10,143,893 | 10,121,452 | |
| - Goodwill | 814,048 | 814,048 | |
| - Other intangible assets | 10 | 9,329,845 | 9,307,404 |
| Right of use assets | 11 | 15,438,151 | 13,839,418 |
| Prepaid expenses | 9 | 4,370,052 | 3,726,970 |
| Deferred tax assets | 23 | 2,627,581 | 2,683,879 |
| TOTAL ASSETS | 56,168,004 | 52,050,212 |
The accompanying notes form an integral part of these consolidated financial statements.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Unaudited | Audited | ||
|---|---|---|---|
| 31 March | 31 December | ||
| Notes | 2025 | 2024 | |
| LIABILITIES AND EQUITY | |||
| Current Liabilities: | 14,037,021 | 14,504,777 | |
| Short term borrowings | 5 | 1,733,658 | 2,750,387 |
| Short term portion of long term borrowings | 5 | 591,882 | 982,997 |
| Obligations under finance leases | 5 | 33,460 | 38,559 |
| Short term lease liabilities | 5 | 845,841 | 711,204 |
| Trade payables | 6 | 6,529,954 | 6,593,553 |
| - Due to related parties | 3,6 | 95,664 | 76,233 |
| - Trade payables to third parties | 6,434,290 | 6,517,320 | |
| Payables related to employee benefits | 12 | 888,220 | 573,473 |
| Other payables | 7 | 397,102 | 450,579 |
| - Due to related parties | 3,7 | 18,244 | 20,080 |
| - Other payables to third parties | 378,858 | 430,499 | |
| Deferred income | 9 | 1,993,088 | 1,774,976 |
| Short term provisions | 282,342 | 249,091 | |
| - Short term provisions for employment benefits | 12 | 185,971 | 150,380 |
| - Other short term provisions | 14 | 96,371 | 98,711 |
| Current tax liabilities | 23 | 741,474 | 379,958 |
| Non-current Liabilities: | 14,912,411 | 11,643,779 | |
| Long term borrowings | 5 | 2,003,052 | - |
| Obligations under finance leases | 5 | 12,185 | 15,484 |
| Long term lease liabilities | 5 | 5,335,162 | 4,294,203 |
| Other payables | 1,020,941 | 1,070,023 | |
| - Other payables to third parties | 7 | 1,020,941 | 1,070,023 |
| Deferred income | 9 | 1,052 | 1,159 |
| Long term provisions | 264,651 | 224,113 | |
| - Long term provisions for employee benefits | 12 | 264,651 | 224,113 |
| Deferred tax liabilities | 23 | 6,275,368 | 6,038,797 |
| EQUITY: | 27,218,572 | 25,901,656 | |
| Equity Attributable to the Owner of the Company: | 26,114,774 | 24,903,759 | |
| Share capital | 16 | 191,012 | 191,012 |
| Adjustments for paid-in capital | 3,504,738 | 3,504,738 | |
| Share premium | 4,204,499 | 4,204,499 | |
| Treasury shares | 16 | (863,742) | (863,742) |
| Other comprehensive income or expenses that will not be reclassified | (35,105) | (93,748) | |
| - Accumulated gain/(loss) on remeasurement of defined benefit plans | (35.105) | (93,748) | |
| Other comprehensive income or expenses that will be reclassified | (17,264) | 130 | |
| - Foreign currency translation differences related to the translation of | |||
| foreign operations | (17,264) | 130 | |
| Restricted reserves | 104,191 | 104,191 | |
| Accumulated income | 16 | 17,856,679 | 12,181,771 |
| Net profit for the period | 1,169,766 | 5,674,908 | |
| Non-controlling interest | 1,103,798 | 997,897 | |
| TOTAL LIABILITIES AND EQUITY | 56,168,004 | 52,050,212 |
The accompanying notes form an integral part of these consolidated financial statements.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Unaudited | Audited | ||
|---|---|---|---|
| 1 January-31 | 1 January-31 | ||
| Dipnotlar | March 2025 | March 2024 | |
| PROFIT OR LOSS | |||
| Revenue | 17 | 11,754,257 | 10,993,413 |
| Cost of sales (-) | 17 | (8,521,835) | (8,126,997) |
| GROSS PROFIT | 3,232,422 | 2,866,416 | |
| General administration expenses (-) | 18 | (1,077,754) | (895,873) |
| Other income from operating activities | 19 | 518,260 | 397,490 |
| Other expenses from operating activities (-) | 19 | (416,009) | (380,977) |
| OPERATING PROFIT | 2,256,919 | 1,987,056 | |
| Income from investing activities | 20 | 222 | 298 |
| Expense from investing activities (-) | 20 | (2,094) | - |
| OPERATING PROFIT BEFORE FINANCE EXPENSE | 2,255,047 | 1,987,354 | |
| Finance expenses (-) | 21 | (953,860) | (823,682) |
| Monetary gain/(loss) | 22 | 643,911 | 1,641,195 |
| NET PROFIT BEFORE TAX | 1,945,098 | 2,804,867 | |
| Tax expense from operations | (669,431) | (1,766,428) | |
| Current tax expense | 23 | (396,110) | (239,987) |
| Deferred tax gain/loss net | 23 | (273,321) | (1,526,441) |
| NET PROFIT | 1,275,667 | 1,038,439 | |
| Allocation of net profit | |||
| Non-controlling interest | 105,901 | 95,206 | |
| Equity holders of the parent | 1,169,766 | 943,233 | |
| NET PROFIT FOR THE YEAR | 1,275,667 | 1,038,439 | |
| Basic gain per share | 24 | 6,12 | 4,53 |
| OTHER COMPREHENSIVE EXPENSES | |||
| Items that will not be reclassified subsequently to profit or loss | |||
| Remeasurement of defined benefit plans | 78,191 | (42,039) | |
| Income tax relating to items that will not be reclassified | |||
| subsequently | (19,548) | 10,510 | |
| Items that will be reclassified to profit or loss | |||
| Foreign currency translation differences | (17,394) | - | |
| TOTAL COMPREHENSIVE INCOME | 1,316,916 | 1,006,910 | |
| Total comprehensive profit distribution | |||
| Non-controlling interest | 105,901 | 95,207 | |
| Equity holders of the Parent | 1,211,015 | 911,703 | |
| Total Comprehensive Income | 1,316,916 | 1,006,910 |
The accompanying notes form an integral part of these consolidated financial statements
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Positive | Accumulated | Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| distinction | gain/(loss) on | Foreign | Attributable | |||||||||
| from share | remeasurement | currency | to the Owner | Non | ||||||||
| Share capital |
capital adjustment |
Share premium |
Treasury shares |
of defined benefit plans |
translation differences |
Restricted reserves |
Accumulated deficit |
Net profit for the period |
of the Company |
controlling interest |
Total equity |
|
| Balance as at January 1, 2024 | 208,037 | 3,506,451 | 4,204,499 | (3,059,904) | (64,815) | - | 104,102 | 8,045,321 | 7,197,853 | 20,141,544 | 345,293 | 20,486,837 |
| Other comprehensive income for the period, net | ||||||||||||
| of tax | - | - | - | - | 31,529 | - | - | - | - | 31,529 | - | 31,529 |
| Net profit for the period | - | - | - | - | - | - | - | - | 943,233 | 943,233 | (19,547) | 923,686 |
| Total comprehensive gain/(loss) for the period | - | - | - | - | 31,529 | - | - | - | 943,233 | 974,762 | (19,547) | 955,215 |
| Transfers | - | - | - | - | - | - | - | 7,197,853 | (7,197,853) | - | - | - |
| Increase/(decrease) due to share repurchase | ||||||||||||
| transactions | - | - | - | (503,730) | - | - | - | - | - | (503,730) | - | (503,730) |
| Balance as at March 31, 2024 | 208,037 | 3,506,451 | 4,204,499 | (3,563,634) | (33,286) | - | 104,102 | 15,243,174 | 943,233 | 20,612,576 | 325,746 | 20,938,322 |
| -- | ||||||||||||
| Balance as at January 1, 2025 | 191,012 | 3,504,738 | 4,204,499 | (863,742) | (93,748) | 130 | 104,191 | 12,181,771 | 5,674,908 | 24,903,759 | 997,897 | 25,901,656 |
| Other comprehensive income for the period, net | ||||||||||||
| of tax | - | - | - | - | 58,643 | (17,394) | - | - | - | 41,249 | - | 41,249 |
| Net profit for the period | - | - | - | - | - | - | - | - | 1,169,766 | 1,169,766 | 105,901 | 1,275,667 |
| Total comprehensive gain/(loss) for the period | - | - | - | - | 58,643 | (17,394) | - | - | 1,169,766 | 1,211,015 | 105,901 | 1,316,916 |
| Transfers | - | - | - | - | - | - | - | 5,674,908 | (5,674,908) | - | - | - |
| Increase/(decrease) due to share repurchase | ||||||||||||
| transactions | - | - | - | - | - | - | - | - | - | - | - | - |
| Balance as at March 31, 2025 | 191,012 | 3,504,738 | 4,204,499 | (863,742) | (35,105) | (17,264) | 104,191 | 17,856,679 | 1,169,766 | 26,114,774 | 1,103,798 | 27,218,572 |
The accompanying notes form an integral part of these consolidated financial statements.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Unaudited 1 | Unaudited 1 | ||
|---|---|---|---|
| January- 31 | January- 31 | ||
| Notes | March 2025 | March 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | 2,327,543 | 2,548,095 | |
| Profit / (loss) for the period | 1,275,667 | 1,038,439 | |
| Adjustments related to reconcilation of net profit / (loss) for the period | 1.748.736 | 1.514.263 | |
| - Adjustments related to depreciation and amortization expenses | 10-11 | 789,230 | 838,226 |
| - Adjustments related to impairment (reversal | 4,332 | 13,500 | |
| Adjustments related to impairment (reversal) of receivables | 6 | 4,332 | 13,500 |
| - Adjustments related to provisions | 93,247 | 48,252 | |
| Adjustments related to (reversal) of provision for employment benefits | 58,643 | 31,529 | |
| Adjustments related to lawsuit (reversal) of provision for lawsuit | 34,604 | 16,723 | |
| - Adjustments related to interest (income) expense | 407,039 | 576,090 | |
| Adjustments related to interest income | 21 | (234,476) | (172,391) |
| Adjustments related to interest expense | 21 | 641,515 | 748,481 |
| - Adjustments related to tax (gain) loss | 23 | 669,431 | 809,257 |
| - Other adjustments related to non-cash items | (20,565) | (33,867) | |
| - Adjustments regarding to (gain) loss on sale of fixed assets | (1,872) | (298) | |
| Adjustments regarding to (gain) loss on sale of tangible assets | (1,872) (192,106) |
(298) (736,897) |
|
| Monetary loss/gain | 22 | (288,350) | 338,661 |
| Changes in working capital - Adjustments related to increase in trade receivables |
(2,184,847) | (1,136,061) | |
| - Adjustments related to increase in inventories | 202,522 | (60,318) | |
| - Adjustments related to increase in trade payables | 538,635 | 940,417 | |
| - Adjustments related to increase in other payables from operations | 940,601 | 307,648 | |
| - Adjustments related to other (increase) decrease in working capital | 214,739 | 286,975 | |
| Adjustments related to increase in other payables from other asset | 214,739 | 286,975 | |
| Cash generated from operations | 2,736,053 | 2,891,363 | |
| - Payments related with provision for employee benefits | (23,583) | (28,065) | |
| - Tax paid | 23 | (379,958) | (316,016) |
| - Payments for other provisions | (5,094) | 780 | |
| - Other cash inflows (outflows) | 6 | 125 | 33 |
| CASH FLOWS FROM INVESTING ACTIVITIES | (1,410,155) | (518,493) | |
| - Proceeds from sales of property, plant, equipment and intangible assets | |||
| 18,578 | 348 | ||
| Proceeds from sales of property, plant, equipment | 10 | 18,578 | 348 |
| - Payment for purchase of property, plant and equipment, intangible assets | (790,061) | (183,093) | |
| Payment for purchase of property, plant and equipment | 10 | (743,960) | (180,266) |
| Payment for purchase of intangible assets | 10 | (46,101) (638,672) |
(2,827) (335,748) |
| - Cash payments for capital expenditures | (12,859) | (2,382,905) | |
| CASH FLOWS FROM FINANCING ACTIVITIES | 2,469,634 | 130,682 | |
| - Cash inflows from borrowings Cash inflows from loans |
2,469,634 | 130,682 | |
| - Bank borrowings paid | (1,340,620) | (875,675) | |
| Cash used for repayment of borrowings | (340,620) | (185,156) | |
| Cash used for repayment of bonds | (1,000,000) | (690,519) | |
| - Repayment of lease liabilities | (544,998) | (428,902) | |
| - Repayment of obligations under finance leases | (8,398) | (23,445) | |
| - Interest paid | (822,953) | (854,226) | |
| - Interest received | 234,476 | 172,391 | |
| - Cash Outflows Related to Repurchase of Own Shares or Reduced Capital (-) | - | (503,730) | |
| NET INCREASE (DECREASE) BEFORE THE EFFECT OF | |||
| FOREIGN CURRENCY TRANSLATION DIFFERENCES | 904,529 | (353.303) | |
| Inflation effect on cash and cash equivalents | (274,475) | (585,069) | |
| Foreign currency translation differences | (17,394) | - | |
| NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS | 4 | 612,660 | (938,372) |
| CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD | 4 | 3,002,094 | 4.469.066 |
| CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | 4 | 3,614,754 | 3,530,694 |
The accompanying notes form an integral part of these consolidated financial statements.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
MLP Sağlık Hizmetleri A.Ş. ("MLP Sağlık") has started its healthcare services operations in 1993, with the opening of Sultangazi Medical Center within the structure of Yükseliş Sağlık Hizmetleri Gıda Tekstil San. Ltd. Şti. in which Muharrem Usta is the majority shareholder. Following this, in 1995, it continues its operations, with the opening of Fatih Hospital under the legal entity of Saray Sağlık Hizmet Ticaret ve Sanayi A.Ş. in which Muharrem Usta was the majority shareholder. In 2005, with the establishment of MLP Sağlık, Fatih and Sultangazi Hospitals were merged under the legal entity of MLP Sağlık.
As of March 31, 2025, MLP is the holding company of 15 subsidiaries (December 31, 2024: 15) (collectively referred as the "Group"), each operating in the healthcare sector in Turkey.
The Company's head office is located in Otakçılar Caddesi No 78 3450, Eyüp, İstanbul.
The Group has an agreement with the Social Security Institution of Turkey (the "SSI") which includes service commitment in all branches disclosed in the Operations Approval Document. SSI is a state enterprise which pays the healthcare expenditures of the citizens of Turkey who are members of the social security system based on the law numbered 5510, and manages social security premiums and short and long term insurance expenses. According to the agreement, the Group is obliged to provide the healthcare services and to issue invoices to the SSI and patients in line with the Communiqué of Health Services published by the SSI. This transaction is performed through Medula, a web based software system, by assessing the right of the patient and obtaining provisions. As a result of the assessment the expenses relating to patients with no SSI, coverage is not charged to SSI. The healthcare expenses provided to the patients are invoiced based on the terms of the Communiqué of Health Services. In this Communiqué SSI determined a price list based on the treatments provided. Invoices are issued based on the price list announced by the Communiqué. SSI has the right not to pay the invoice or make a deduction if the treatments provided are not in compliance with the terms.
The Company is registered to the Capital Markets Board ("CMB") and its shares have been quoted on the Borsa İstanbul A.Ş. ("BİAŞ or "Borsa" or "BİST") since February 13, 2018. In accordance with the resolution numbered 21/655 on July 23, 2010 of CMB; according to the records of Central Registry Agency (CRA); shares representing 26.71% as of March 31 2025, of MLP Sağlık are accepted as "in circulation". As of April 1, 2025, this ratio is 26.71% (Note 16).
The number of employees of the Group as at 31 March 2025 is 13,449 (31 December 2024: 13,278).
Board of Directors has approved the financial statements and delegated authority for publishing it on May 7, 2025.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
As of March 31, 2025, the subsidiaries of the Company are:
| Name | Location and base of operation |
|---|---|
| Temar Tokat Manyetik Rezonans Sağlık Hizmetleri ve Turizm A.Ş. ("Tokat Hastanesi") Samsun Medikal Grup Özel Sağlık Hizmetleri A.Ş. ("Samsun Hastanesi") Kuzey Medikal Pazarlama İnşaat Taşımacılık San. ve Tic. Ltd. Şti. ("Kuzey") Artımed Medikal Sanayi ve Ticaret A.Ş. ("Artımed") MS Sağlık Hizmetleri Ticaret A.Ş. ("MS Sağlık") Mediplaza Sağlık Hizmetleri Ticaret A.Ş. ("Mediplaza") 21. Yüzyıl Anadolu Vakfı ("21.Yüzyıl Anadolu Vakfı") |
Tokat Samsun-İstanbul Ankara Ankara Ankara Gebze – İzmit İstanbul |
| Sotte Sağlık Temizlik Yemek Medikal Turizm Insaat San. ve Tic. A.Ş. ("Sotte Sağlık Temizlik Yemek") BTR Sağlık Hizmetleri A.Ş. ("BTR Sağlık") İstanbul Meditime Sağlık Hizmetleri Ticaret Ltd. Şti. ("Meditime Sağlık") MLP Gaziantep Sağlık Hizmetleri Anonim Şirketi ("MLP Gaziantep Sağlık") Kuzey Doğu Sağlık Hizmetleri ve Tic. A.Ş. ("Kuzey Doğu") Livist Sağlık Hizmetleri Ltd. MLP İzmir Sağlık Hizmetleri A.Ş. MLP Ataşehir Sağlık Hizmetleri A.Ş. |
İstanbul - Ankara İstanbul İstanbul Gaziantep İstanbul Kıbrıs İstanbul - İzmir İstanbul |
The condensed consolidated financial statements of the Group have been prepared in accordance with the Turkish Financial Reporting Standards, ("TFRS") and interpretations as adopted in line with international standards by the Public Oversight Accounting and Auditing Standards Authority of Turkey ("POA") in line with the communiqué numbered II-14.1 "Communiqué on the Principles of Financial Reporting In Capital Markets" ("the Communiqué") announced by the Capital Markets Board of Turkey ("CMB") on June 13, 2013 which is published on Official Gazette numbered 28676.
The Company prepared its condensed interim financial statements for the period ended 31 March 2024 in accordance with ("IAS") 34 "Interim Financial Reporting". The condensed interim financial statements and its accompanying notes are presented in compliance with the format recommended by CMB including its mandatory information. In compliance with the IAS 34, entities have preference in presenting their interim financial statements whether full set or condensed. In this framework, the Company preferred to present its interim financial statements in condensed.
Interim condensed financial statements of the Group do not include all the information and disclosures required in the annual financial statements, therefore should be read in conjunction with the Company's annual financial statements as of 31 December 2024.
The individual financial statements of each Group entity are presented in the currency of the primary economic environment in which the entity operates (its functional currency). For the purpose of the consolidated financial statements, the results and financial position of each entity are expressed in TL. As at 31 March 2025, the functional currency of Kosovo branch of Samsun Medikal Grup Özel Sağlık Hizmetleri A.Ş. is Euro ('EUR'). The income statements of Group companies that present their financial statements in a functional currency other than TL are translated into TL at the average exchange rate for the year. The assets and liabilities of these Group companies are translated into TL at the closing rate. Exchange differences arising on the translation of the opening net assets of these Group companies and differences between the average and closing exchange rates are taken to the currency translation reserve in equity.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
In accordance with the CMB's decision dated 28 December 2023 and numbered 81/1820, issuers and capital market institutions subject to financial reporting regulations applying Turkish Accounting/Financial Reporting Standards are required to apply inflation accounting by applying the provisions of TAS 29 to their annual financial statements for the accounting periods ending on 31 December 2023.
POA made an announcement on 23 November 2023 regarding the scope and application of TAS 29. It stated that the financial statements of the entities applying Turkish Financial Reporting Standards for the annual reporting period ending on or after 31 December 2023 should be presented in accordance with the related accounting principles in TAS 29, adjusted for the effects of inflation.
In this framework, while preparing the consolidated financial statements dated 31 March 2025, 31 December 2024 and 31 March 2024 inflation adjustment has been made in accordance with TAS 29.
The financial statements and related figures for previous periods have been restated for changes in the general purchasing power of the functional currency and, consequently, the financial statements and related figures for previous periods are expressed in terms of the measuring unit current at the end of the reporting period in accordance with TAS 29 Financial Reporting in Hyperinflationary Economies.
TAS 29 applies to the financial statements, including the consolidated financial statements, of each entity whose functional currency is the currency of a hyperinflationary economy. If an economy is subject to hyperinflation, TAS 29 requires an entity whose functional currency is the currency of a hyperinflationary economy to present its financial statements in terms of the measuring unit current at the end of the reporting period.
As at the reporting date, entities operating in Turkey are required to apply TAS 29 "Financial Reporting in Hyperinflationary Economies" for the reporting periods ending on or after 31 December 2023, as the cumulative change in the general purchasing power of the last three years based on the Consumer Price Index ("CPI") is more than 100%.
The table below shows the inflation rates for the relevant years calculated by taking into account the Consumer Price Indices published by the Turkish Statistical Institute (TURKSTAT):
| Three-year cumulative | |||
|---|---|---|---|
| Date | Index | Adjustment coefficient | inflation rates |
| 31.03.2025 | 2,954.69 | 1.00000 | 250% |
| 31.12.2024 | 2,684.55 | 1.10063 | 291% |
| 31.03.2024 | 2,139.47 | 1.38104 | 309% |
The main lines of TAS 29 indexation transactions are as follows:
• As of the balance sheet date, all items other than those stated in terms of current purchasing power are restated by using the relevant price index coefficients. Prior year amounts are also restated in the same way.
• Monetary assets and liabilities are expressed in terms of the purchasing power at the balance sheet date and are therefore not subject to restatement. Monetary items are cash and items to be received or paid in cash.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
• Fixed assets, subsidiaries and similar assets are indexed to their acquisition values, which do not exceed their market values. Depreciation has been adjusted in a similar manner. Amounts included in shareholders' equity have been restated by applying general price indices for the periods in which they were contributed to or arose within the Company.
• All items in the income statement, except for the effects of non-monetary items in the balance sheet on the income statement, have been restated by applying the multiples calculated over the periods when the income and expense accounts were initially recognised in the financial statements.
• The gain or loss arising on the net monetary position as a result of general inflation is the difference between the adjustments to non-monetary assets, equity items and income statement accounts. This gain or loss on the net monetary position is included in net profit.
The impact of the application of TAS 29 Inflation Accounting is summarised below:
Amounts in the statement of financial position that are not expressed in terms of the measuring unit current at the end of the reporting period are restated. Accordingly, monetary items are not restated because they are expressed in the currency of the reporting period. Non-monetary items are required to be restated unless they are expressed in terms of the currency in effect at the end of the reporting period.
The gain or loss on the net monetary position arising on restatement of non-monetary items is recognised in profit or loss and presented separately in the statement of comprehensive income.
All items in the statement of profit or loss are expressed in terms of the measuring unit current at the end of the reporting period. Therefore, all amounts have been restated by applying changes in the monthly general price index.
Cost of inventories sold has been restated using the restated inventory balance.
Depreciation and amortisation expenses have been restated using the restated balances of property, plant and equipment, intangible assets, investment property and right-of-use assets.
All items in the statement of cash flows are expressed in terms of the measuring unit current at the end of the reporting period.
The financial statements of a subsidiary whose functional currency is the currency of a hyperinflationary economy are restated by applying the general price index before they are included in the consolidated financial statements prepared by the parent company. If the subsidiary is a foreign subsidiary, its restated financial statements are translated at the closing rate.
When consolidating financial statements with different reporting period ends, all monetary and non-monetary items are restated in accordance with the measuring unit current at the date of the consolidated financial statements.
Relevant figures for the previous reporting period are restated by applying the general price index so that the comparative financial statements are presented in the measuring unit applicable at the end of the reporting period. Information disclosed for prior periods is also expressed in terms of the measuring unit current at the end of the reporting period.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
The Group's consolidated financial statements have been prepared in comparison with the previous period in order to give accurate trend analysis regarding the financial position and performance. Where necessary, comparative figures have been reclassified to conform to the presentation of the current period consolidated financial statements and significant changes are explained.
Within the scope of interim financial statements for the period of January 1 – March 31, 2024, the inflation effect of deferred tax amounting to TRY 957,171, included in Note 22 – Deferred Tax Liabilities Movement Table, has been classified under the 'Monetary Gain/(Loss)' line item in the statement of profit or loss.
The details of the Company's subsidiaries as at March 31, 2025 and December 31, 2024 are as follows:
| Subsidiaries | Place of incorporation and operation |
31 March 2025 |
31 December 2024 |
Principal activity |
|---|---|---|---|---|
| Tokat Hastanesi | Tokat | %58.84 | %58.84 | Hospital Services |
| Samsun Hastanesi (2) | Samsun | %80.00 | %80.00 | Hospital Services |
| MS Sağlık | Ankara | %100.00 | %100.00 | Hospital Services |
| Mediplaza | Gebze-İzmit | %75.00 | %75.00 | Hospital Services |
| BTR Sağlık Hizmetleri | İstanbul | %100.00 | %100.00 | Hospital Services |
| Meditime Sağlık | İstanbul | %100.00 | %100.00 | Hospital Services |
| MLP Gaziantep Sağlık | Gaziantep | %100.00 | %100.00 | Hospital Services |
| Sotte Sağlık Temizlik Yemek | İstanbul - Ankara | %100.00 | %100.00 | Hospital Services |
| Livist Sağlık Hizmetleri Ltd. | Kıbrıs | %99.99 | %99.99 | Hospital Services |
| MLP İzmir | İstanbul - İzmir | %65.00 | %65.00 | Hospital Services |
| Kuzey | Ankara | %100.00 | %100.00 | Ancillary Services |
| Artımed | Ankara | %100.00 | %100.00 | Ancillary Services |
| 21. Yüzyıl Anadolu Vakfı (1) | İstanbul | %100.00 | %100.00 | Ancillary Services |
| Kuzey Doğu | İstanbul | %100.00 | %100.00 | Ancillary Services |
| MLP Ataşehir | İstanbul | %64.00 | %64.00 | Ancillary Services |
(1) Represents voting power held. In 2011, the Group with the help of its real person shareholders decided to establish a medical university. Based on current legislation, foundations have to be owned by real persons rather than companies and since MLP Sağlık could not be the shareholder of an association, Muharrem Usta, one of the shareholders in the company, was assigned as the chairman of the board of the foundation. The purpose of the foundation is to establish a medical university in order to align one of the hospitals of the Group to that university. Although, MLP Sağlık has no shareholder interest in the foundation, the financial statements of the foundation are consolidated to the financial statements in accordance with TFRS 10 as the Company achieved the control by having power and the ability to use its power on the future benefit and cost of the foundation. In addition, the Company has rights to the financial and operating policies of the university from its involvement with the investee.
(2) As of October 2024, a hospital operating in Kosovo was opened to be affiliated to Samsun Hospital. The functional …..currency of the related branch is Euro.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:
The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.
In cases where the Company has no majority voting rights on the company/asset invested, it still has the control power over that company/asset if the Company alone has sufficient voting rights to manage the investment operations of that company/asset. The Company considers all events and requirements including the items listed below to evaluate if its voting power is sufficient to get control power in an investment:
Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary.
Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.
Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with those used by other members of the Group.
All intra-group assets and liabilities, equities, income and expenses and cash flows resulting from of Group companies' transactions are eliminated on consolidation.
Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's interests and the noncontrolling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to owners of the Company.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
When the Group loses control of a subsidiary, a gain or loss is recognised in profit or loss and is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), and liabilities of the subsidiary and any non-controlling interests. All amounts previously recognised in other comprehensive income in relation to that subsidiary are accounted for as if the Group had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified to profit or loss or transferred to another category of equity as specified/permitted by applicable IFRSs). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under IAS 39, when applicable, the cost on initial recognition of an investment in an associate or a joint venture.
Significant changes made in accounting policies are applied retrospectively and prior year financial statements are restated. In current period, the Group has no changes in its accounting policies other than the change disclosed in Note 2.1.
If changes in accounting estimates are for only one period, changes are applied on the current year but if the changes in accounting estimates are for the following periods, changes are applied both on the current and the following years prospectively. In the current period, the Group has no changes in the accounting estimates and errors.
Preparation of consolidated financial statements requires management to make estimations and assumptions which may affect the reported amounts of assets and liabilities as of the statement of financial position date, the disclosure of contingent assets and liabilities and the reported amounts of income and expenses during the financial period. The accounting assessments, estimates and assumptions are reviewed considering past experiences, other factors and reasonable expectations about future events under current conditions. Although the estimations and assumptions are based on the best estimates of the management's existing incidents and operations, they may differ from the actual results.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
a) Amendments that are mandatorily effective from 2025
Amendments to TAS 21 Lack of Exchangeability
The amendments contain guidance to specify when a currency is exchangeable and how to determine the exchange rate when it is not. Amendments are effective from annual reporting periods beginning on or after 1 January 2025.
The Group evaluates the effects of these standards, amendments and improvements on the consolidated financial statements.
The Group has not yet adopted the following standards and amendments and interpretations to the existing standards:
TFRS 17 Insurance Contracts
Amendments to TFRS 17 Initial Application of TFRS 17 and TFRS 9 — Comparative Information
TFRS 17 requires insurance liabilities to be measured at a current fulfillment value and provides a more uniform measurement and presentation approach for all insurance contracts. These requirements are designed to achieve the goal of a consistent, principle-based accounting for insurance contracts. TFRS 17 has been deferred for insurance, reinsurance and pension companies for a further year and will replace TFRS 4 Insurance Contracts on 1 January 2026.
Amendments have been made in TFRS 17 in order to reduce the implementation costs, to explain the results and to facilitate the initial application.
The amendment permits entities that first apply TFRS 17 and TFRS 9 at the same time to present comparative information about a financial asset as if the classification and measurement requirements of TFRS 9 had been applied to that financial asset before. Amendments are effective with the first application of TFRS 17.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
Transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note.
The details of short-term receivables and payables as of 31 March 2025 are as follows:
| 31 March 2025 | ||||
|---|---|---|---|---|
| Receivables | Payables | |||
| Short-term | Short-term | |||
| Shareholders | Trade | Non-trade | Trade | Non-trade |
| Muharrem Usta (*) | - | 283,107 | - | 50 |
| Adem Elbaşı | - | 12,946 | - | - |
| Hikmet Çavuş | - | 23,805 | - | - |
| Mehmet Fatih Yalçınkaya | - | - | - | 18,183 |
| Other companies controlled by the shareholders | ||||
| A ve A Sağlık A.Ş. (2) | 326 | - | 31,398 | - |
| Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. (4) | - | - | 16,508 | - |
| Pozitif Medikal Sistemler San. ve Tic. Ltd. Şti. | 2 | - | 509 | - |
| Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1) | 792 | - | 22,569 | - |
| Saray Eczanesi | - | - | 369 | - |
| MLP Healthcare Uk (5) | 33,662 | - | - | - |
| Samsunpark Öz. Sağ. Tıbbı Malz. Tur. Tem. Tic. A.Ş. (3) | - | - | 24,146 | - |
| Tokat Emar Sağlık Hiz. Ltd. Şti. | - | - | 165 | - |
| Özel Gebze Sentez Sağlık Hizmetleri Ve Tic. A.Ş. | - | - | - | 7 |
| Other | 440 | 140 | - | 4 |
| 35,222 | 319,998 | 95,664 | 18,244 |
(*) Non-trade receivables from Muharrem Usta is short term due date and interest charge from the current value of internal debt ratio of Group.
(1) A ve A Özel Sağ. Hiz. ve Cih. Teks. San. Tic. Ltd. Şti. provides cleaning materials for the hospitals.
(2) Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides turn key project management services for the furniture & fixture and leasehold improvements of the hospitals and audit of construction of the Group hospitals.
(3) Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. provides cleaning, catering and laundry services for the Group.
(4) Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. provides cleaning and catering services for the Group.
(5) MLP Healthcare UK operates in the field of healthcare services and provides consultancy services in this area.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| 31 December 2024 | ||||
|---|---|---|---|---|
| Receivables | Payables | |||
| Short-term | Short-term | |||
| Shareholders | Trade | Non-trade | Trade | Non-trade |
| Muharrem Usta (*) | - | 276,741 | - | 55 |
| Adem Elbaşı | - | 12,307 | - | - |
| Hikmet Çavuş | - | 11,849 | - | |
| Fatih Mehmet Yalçınkaya | - | - | - | 20,013 |
| Other companies controlled by the shareholders | ||||
| A ve A Sağlık A.Ş. (2) | - | - | 23,175 | - |
| Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1) | 233 | - | 23,189 | - |
| Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. (4) | - | - | 9,804 | - |
| Pozitif Medikal Sistemler San. ve Tic. Ltd. Şti. | - | - | 560 | - |
| Samsunpark Özel Sağlık Tıbbı | ||||
| Malz. İnş. Tur. Tem. Tic. A.Ş. (3) | - | - | 19,248 | - |
| MLP Healthcare Uk (5) | 32,227 | - | ||
| Saray Eczanesi | - | - | 75 | - |
| Tokat Emar Sağlık Hiz. Ltd. Şti. | - | - | 182 | - |
| Özel Gebze Sentez Sağlık Hizmetleri Ve Tic. A.Ş. | - | - | - | 7 |
| Other | 88 | 153 | - | 5 |
| 32,548 | 301,050 | 76,233 | 20,080 |
(*) Non-trade receivables from Muharrem Usta is short term due date and interest charge from the current value of internal debt ratio of Group.
(1) Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides turnkey project management services for the furniture & fixture and leasehold improvements of the hospitals and audit of ongoing construction of the Group hospitals.
(2) A ve A Özel Sağ. Hiz. ve Cih. Teks. San. Tic. Ltd. Şti. provides cleaning materials for the hospitals.
(3) Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. provides cleaning, catering and laundry services for the Group.
(4) Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. provides cleaning and catering services for the Group.
(5) MLP Healthcare UK operates in the field of healthcare services and provides consultancy services in this area.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Advances given to related parties, prepaid expenses | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1) | 13,850 | 15,244 |
| Sanport Gayrimenkul Geliştirme İnş.Ve Tic.A.Ş | 279 | 306 |
| Atk Sağlık Hizmetleri Ve Danışmanlık A.Ş. | 11 | - |
| A ve A Sağlık A.Ş. | 211 | - |
| 14,351 | 15,550 |
| Fixed asset advances given to related parties | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1) | 1,544,262 | 1,544,262 |
| 1,544,262 | 1,544,262 |
| 31 March 2025 | 31 December 2024 | |||
|---|---|---|---|---|
| Lease liabilities from related parties | Short-term | Long-term | Short-term | Long-term |
| Sanport Gayrimenkul Geliştirme İnş. ve Tic. A.Ş | 304,315 | 861,380 | 216,966 | - |
| Fom Grup Mimarlık İnşaat Ve Tic. A.Ş. | 43,728 | 74,241 | 41,857 | 85,240 |
| Atakum Özel Sağlik Hizmetleri İnş.Tur. ve San. Tic. A.Ş. | 11,953 | 429,670 | 20,835 | 438,285 |
| Özel Gebze Sentez Sağlık Hizmetleri ve Tic. A.Ş. | 37,425 | 34,915 | 24,408 | 31,363 |
| Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş. | 13,072 | 17,585 | 13,512 | 23,297 |
| 410,493 | 1,417,791 | 317,578 | 578,185 |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| 1 January-31 | 1 January-31 | |
|---|---|---|
| Purchases from related parties | March 2025 | December 2024 |
| A ve A Sağlık A.Ş. (1) | 34,654 | 33,887 |
| Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (2) | 15,150 | 18,762 |
| 49,804 | 52,649 |
(1) Cleaning material purchases
(2) Hospital rent expenses
| Operating expenses (including purchase of services) | 1 January-31 March 2025 |
1 January-31 December 2024 |
|---|---|---|
| Sanport Gayrimenkul Geliştirme İnş. ve Tic.A.Ş (1)(6) | 141,285 | 100,777 |
| Samsunpark Özel Sağ. Tıbbi Malz. İnş. Tur. Tem. Tic. A.Ş. (3) | 30,090 | 37,513 |
| Atakum Özel Sağlik Hiz. İnş. Turizm ve San. Tic. A.Ş. (1)(6) | 38,483 | 27,896 |
| Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. (3) | 18,376 | 17,244 |
| Livart Tüp Bebek Özel Sağlık Hizm. A.Ş. (2) | 23,438 | 22,253 |
| Atk Sağlık Hizmetleri Ve Danışmanlık A.Ş. | 10,266 | 4,599 |
| Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş. (1)(6) | 11,747 | 12,290 |
| Tokat Emar Sağlık Hiz. Ltd. Şti. (2) (4) | 3,738 | 3,338 |
| Saray Eczanesi (5) | 307 | 402 |
| Özdenler Sağ. Hiz. Dan. Turz. Gıd. San. Tic. Ltd. Şti. (2) | 980 | 728 |
| 278,710 | 227,040 |
(1) Hospital rent expenses
(2) Doctor expenses
(3) Cleaning, catering and laundry services
(4) Medical equipment rent expenses
(5) Drug purchase expenses
(6) Material purchase expenses
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| 1 January-31 | 1 January-31 | |
|---|---|---|
| Sales to related parties | March 2025 | December 2024 |
| A ve A Sağlık A.Ş. (1) | 305 | 355 |
| Cotyora Med.Özel Sağ.Taah. Hz. İnş. Tr. Loj. Ltd. Şti. | 520 | 364 |
| Samsunpark Özel Sağlık Tıbbi Malz. İnş. Turizm. Tem. Tic. A.Ş. | 719 | 604 |
| Fom Grup Mimarlık İnşaat ve Tic. A.Ş. | 636 | 308 |
| Adem Elbaşı | 1,456 | 887 |
| Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş. | 80 | 78 |
| Hikmet Çavuş | 375 | - |
| MLP Health Uk | 1,666 | - |
| Miniso Mağazacılık A.Ş. | 368 | 314 |
| 6,125 | 2,910 |
| Interest income from related parties | 1 January-31 March 2025 |
1 January-31 December 2024 |
|---|---|---|
| Muharrem Usta | 32,410 | 25,258 |
| 32,410 | 25,258 |
Key management personnel comprise general managers, deputy general managers and chief physicians of hospitals and head office management team.
The remuneration of directors and other members of key management during the year were as follows:
| 1 January-31 March 2025 |
1 January-31 December 2024 |
|
|---|---|---|
| Salaries and other short term benefits | 64,501 | 49,320 |
| 64,501 | 49,320 |
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Cash on hand | 42,185 | 48,176 |
| Cash at banks | 3,559,073 | 2,912,425 |
| - Demand deposit | 1,922,158 | 729,003 |
| - Time deposit | 1,636,915 | 2,183,422 |
| Other cash equivalents (*) | 13,496 | 41,493 |
| 3,614,754 | 3,002,094 |
(*) Other cash equivalents consist of credit card receivables from banks.
As of 31 March 2025, the interest rates of the Group's time deposits in TRY is respectively 10%-44,50% and their terms are less than 3 months. (31 December 2024: 10%-48%)
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Short Term Bank Borrowings | 563,032 | 549,132 |
| Short Term Bonds Issued | 1,000,000 | 2,201,255 |
| Current Portion of Long Term Borrowings | 591,882 | 583,362 |
| - Current portion of long-term bank loans | 591,882 | 583,362 |
| Interest Expense Accruals | 170,626 | 399,635 |
| 2,325,540 | 3,733,384 | |
| Long Term Bonds Issued | 2,003,052 | - |
| 2,003,052 | - | |
| Total Borrowings | 4,328,592 | 3,733,384 |
The Group issued sukuk amounting to 1,000,000 TL with a maturity of 18 months, to be sold to qualified investors on 12 December 2023. The principal payment will be paid on 12.06.2025, which is the maturity date, and the interest rate is 50%.
The reconciliation of the liabilities arising from financing activities as of 1 January- 31 March 2025 and 1 January- 31 December 2024 are as follows:
| 1 January 2025 |
Financing cash flows |
Foreign exchange effect (Note 21) |
Other (*) | Effect of Inflation |
31 March 2025 | |
|---|---|---|---|---|---|---|
| Bank Loans | 3,733,384 | 781,856 | 156,375 | - | (343,023) | 4,328,592 |
| Finance lease obligations | 54.043 | (3,457) | 2,350 | - | (7,291) | 45,645 |
| Lease obligations | 5,005,407 | (544,998) | 9,061 | 2,166,278 | (454,745) | 6,181,003 |
| 8,792,834 | 233,401 | 167,786 | 2,166,278 | (805,059) | 10,555,240 |
| 1 January | Financing | Foreign exchange effect |
Effect of | 31 December | ||
|---|---|---|---|---|---|---|
| 2024 | cash flows | (Note 21) | Other (*) | Inflation | 2024 | |
| Bank Loans | 5,943,050 | (382,907) | - | - | (1,826,759) | 3,733,384 |
| Finance lease obligations | 86.397 | (8,981) | 666 | - | (24,039) | 54,043 |
| Lease obligations | 3,593,490 | (1,546,515) | 12,218 | 4,045,500 | (1,099,286) | 5,005,407 |
| 9,622,937 | (1,938,403) | 12,884 | 4,045,500 | (2,950,084) | 8,792,834 |
(*) Some of the lease obligations within the scope of TFRS 16 are due to the re-measurement of the reduced lease obligations and interest expenses due to the change in the lease payments realized within the period.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
As of March 31, 2025 and December 31, 2024 the repayment schedule of the total borrowings as follows: 31 March 2025
| Weighted Average Effective Interest | ||||
|---|---|---|---|---|
| Currency Type | Rate | Current | Non-Current | Total |
| TRY | 45.12% | 2,288,040 | - | 2,288,040 |
| TRY | TLRef-5.80 | 37,500 | - | 37,500 |
| EUR | EurLibor+0.89+3.40+3.60 | - | 2,003,052 | 2,003,052 |
| 2,325,540 | 2,003,052 | 4,328,592 |
| Weighted Average Effective Interest | ||||
|---|---|---|---|---|
| Currency Type | Rate | Current | Non-Current | Total |
| TL | 49.25% | 3,650,837 | - | 3,650,837 |
| TL | TLRef+13.55-TLRef+5.80 | 82,547 | - | 82,547 |
| 3,733,384 | - | 3,733,384 |
As of March 31, 2025, there are no blocked cash accounts related to the group's loans (December 31, 2024: None).
As at March 31, 2025 and December 31, 2024 the repayment schedule of the borrowings in TRY are as follows:
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Interest expense accruals | 170,626 | 399,636 |
| To be paid within 1 year (*) | 2,154,914 | 3,333,748 |
| To be paid between 1-2 years | 1,377,456 | - |
| To be paid between 2-3 years | 133,702 | - |
| To be paid between 3-4 years | 133,702 | - |
| To be paid between 4-5 years | 133,702 | - |
| To be paid between 5-10 years | 224.490 | - |
| 4,328,592 | 3,733,384 |
(*) TRY 500,000 of the loans to be paid within one year consists of revolving loans and TRY 1.000.000 part consists of bond payments which will be redeemed within 1 year.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
The Group has seven banks consisting of Türkiye İş Bankası A.Ş., Türkiye Garanti Bankası A.Ş., Denizbank A.Ş., Denizbank AG, Odeabank A.Ş., ING European Financial Services PLC and ING Bank A.Ş. Syndication loan was signed on December 31, 2015. The use of the syndicated loan took place in February 2016. Regarding the loan in question, the share pledge on 25% of the Group's non-public shares has been removed. The commercial enterprise pledge and the Group's bank account pledge regarding the Company's shares in companies that are subsidiaries of the Group and all fixed assets owned by the Company continue. In addition, the Group's receivables arising from medical tourism contracts and insurance policies have also been assigned.
The syndicate loan includes a number of financial covenants stated below:
The Debt Service Coverage Ratio ("DSCR") cannot be below 1.1 during the term of the agreement (2016-2025). DSCR is tested every six months starting from December 31, 2016.
Net debt to EBITDA Ratio cannot be above x4.0 for the year ended December 31, 2016 and for the six months period ended June 30, 2017, x3.5 for the year ended December 31, 2017 and for the six months period ended June 30, 2018, x3.0 for the year ended December 31, 2018 and for the six months period ended June 30, 2019 and x2.5 for the remaining period of the syndicate loan.
The Group has the following finance lease obligations which arose mainly due to lease of medical machinery and equipment:
| Minimum lease paymets | Present value of minimum lease payments |
|||
|---|---|---|---|---|
| 31 March 2025 | 31 December 2024 | 31 March 2025 | 31 December 2024 | |
| Within one year | 39,200 | 54,049 | 33,460 | 38,560 |
| In the second to sixth years inclusive | 14,275 | 10,040 | 12,185 | 15,483 |
| 53,475 | 64,089 | 45,645 | 54,043 | |
| Less: Future finance charges | (7,830) | (10,046) | - | - |
| Present value of finance lease obligations | 45,645 | 54,043 | 45,645 | 54,043 |
| Current trade receivables | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Trade receivables | 5,426,466 | 4,966,244 |
| Notes receivables | 919 | 1,013 |
| Trade receivables from related parties (Note 3) | 35,222 | 32,548 |
| Income accruals from continuing treatments | 2,331,267 | 1,838,693 |
| Other trade income accruals | 15,384 | 23,103 |
| Allowance for doubtful receivables (-) | (151,316) | (162,030) |
| 7,657,942 | 6,699,571 |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Non-current trade receivables | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Income accruals | 1.053 | 1.159 |
| 1.053 | 1.159 |
Allowance for doubtful receivables for the trade receivables is determined depending on past experiences of irrecoverable amounts.
As of March 31, 2025, trade receivables of an initial value of TRY 151,316 (December 31, 2024: TRY 162,030) were fully impaired and fully provided for. No collaterals are received in relation to these trade receivables.
| 1 January-31 March | 1 January-31 December | |
|---|---|---|
| Movement of allowance for doubtful receivables | 2025 | 2024 |
| Opening balance | 162,030 | 223,476 |
| Charge for the period (Note 18) | (4,332) | (10,007) |
| Collections | (125) | (95) |
| Inflation effect | (6,257) | (51,344) |
| Ending balance | 151,316 | 162,030 |
| Current trade payables | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Trade payables | 4,586,375 | 4,605,130 |
| Trade payables due to related parties (Note 3) | 95,664 | 76,233 |
| Other expense accruals | 1,800,560 | 1,862,465 |
| Other trade payables | 47,355 | 49,725 |
| 6,529,954 | 6,593,553 |
| Other current receivables | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Receivables from tax office | 37,456 | 41,226 |
| Non-trading receivables due from related parties (Note 3) | 1,279 | 1,153 |
| Deposits given | 319,998 | 301,050 |
| Other miscellaneous receivables | 64,148 | 49,355 |
| 422,881 | 392,784 | |
| Other non-current receivables | 31 March 2025 | 31 December 2024 |
| Deposits and guarantees given | 986,086 | 820,596 |
986,086 820,596
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Other current payables | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Other taxes and funds payable | 211,709 | 246,589 |
| Payables relating to business combinations (*) | 155,835 | 171,383 |
| Non-trading payables due to related parties (Note 3) | 18,244 | 20,080 |
| Other miscellaneous payables | 11,314 | 12,527 |
| 397,102 | 450,579 | |
| Other non-current payables | 31 March 2025 | 31 December 2024 |
| Payables relating to business combinations (*) | 1,020,941 | 1,070,023 |
| 1,020,941 | 1,070,023 |
(*) The Group has committed a payment schedule that will continue in the upcoming years as a result of some business combination contracts signed in 2014, 2020, 2022 and 2024. This liability represents the net present value of forthcoming payments. The weighted average interest rate of TL denominated contracts is 35% and the average maturity is 9 years (2024: 35% and 9 years). The weighted average interest rate of USD denominated contracts is 9% and the maturity is 2 years (2024:9% and 2 years).
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Medical consumables inventory | 683,264 | 917,289 |
| Pharmaceutical inventory | 216,108 | 186,572 |
| Other inventories | 2,797 | 830 |
| 902,169 | 1,104,691 |
| Short term prepaid expenses | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Advances given (*) | 377,170 | 376,931 |
| Prepaid insurance expenses | 101,949 | 168,832 |
| Prepaid rent expenses | 44,254 | 67,831 |
| Prepaid sponsorship expenses | 4,335 | 2,833 |
| Other | 289,161 | 72,551 |
| 816,869 | 688,978 |
(*) Advances consist of mainly the turnkey hospital projects regarding new and renovated hospitals and the order advances given for the construction services for the hospitals under construction.
| Long term prepaid expenses | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Fixed asset advances given | 2,809,323 | 2,170,651 |
| Fixed asset advances given to related parties (Note 3) | 1,544,262 | 1,544,262 |
| Prepaid rent expenses | - | 87 |
| Other | 16,467 | 11,970 |
| 4,370,052 | 3,726,970 |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Short term accrued income | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Advances received (*) | 1,968,828 | 1,736,595 |
| Deferred revenue | 24,260 | 38,381 |
| 1,993,088 | 1,774,976 |
(*) Advances are received from mainly local and medical tourism related patients with regards to cost of their treatments. After treatments are completed, realized remunerations are netted with advances.
| Long term accrued income | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Deferred revenue | 1,052 | 1,159 |
| 1,052 | 1,159 |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Land | Buildings | Machinery and equipments |
Vehicles | Furniture and fixtures |
Leased assets |
Leasehold improvements |
Construction in progress |
Total | |
|---|---|---|---|---|---|---|---|---|---|
| Cost | |||||||||
| Opening balance as of 1 January 2025 | 1,181,905 | 15,358 | 9,929,545 | 28,069 | 3,790,250 | 5,568,981 | 10,068,540 | 606,776 | 31,189,424 |
| Additions | - | - | 101,441 | - | 166,596 | - | 49,966 | 425,957 | 743,960 |
| Disposals | - | - | - | - | (1,222) | - | (16,134) | - | (17,356) |
| Foreign currency translation differences | - | - | (8,992) | - | - | - | - | - | (8,992) |
| Closing balance as of 31 March 2025 | 1,181,905 | 15,358 | 10,021,994 | 28,069 | 3,955,624 | 5,568,981 | 10,102,372 | 1,032,733 | 31,907,036 |
| Accumulated depreciations | |||||||||
| Opening balance as of 1 January 2025 | - | (5,588) | (7,549,687) | (23,856) | (3,073,748) | (5,541,538) | (6,451,937) | - | (22,646,354) |
| Charge for the period (*) | - | (72) | (169,937) | (269) | (68,130) | (27,443) | (209,440) | - | (475,291) |
| Disposals | - | - | - | - | 650 | - | - | - | 650 |
| Closing balance as of 31 March 2025 | - | (5,660) | (7,719,624) | (24,125) | (3,141,228) | (5,568,981) | (6,661,377) | - | (23,120,995) |
| Carrying value as of 31 March 2025 | 1,181,905 | 9,698 | 2,302,370 | 3,944 | 814,396 | - | 3,440,995 | 1,032,733 | 8,786,041 |
(*) Depreciation and amortization expense of TRY 458,814 (January 1 - March 31, 2024: TRY 404,595) has been charged in 'cost of service', TRY 40,137 (January 1-March 31, 2024: TRY 55,794) has been charged in 'operating expenses' for the period ended between January 1- March 31, 2025.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Machinery | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Land | Buildings | and equipments |
Vehicles | Furniture and fixtures |
Leased assets | Leasehold improvements |
Construction in progress |
Total | |
| Cost | |||||||||
| Opening balance as of 1 January 2024 | 229,798 | 15,359 | 9,166,754 | 25,209 | 3,254,740 | 5,538,597 | 8,856,518 | 103,839 | 27,190,814 |
| Additions | - | - | 70,597 | - | 43,558 | - | 64,696 | 1,414 | 180,265 |
| Disposals | - | - | - | - | (50) | - | - | - | (50) |
| Closing balance as of 31 March 2024 | 229,798 | 15,359 | 9,237,351 | 25,209 | 3,298,248 | 5,538,597 | 8,921,214 | 105,253 | 27,371,029 |
| Accumulated depreciations | |||||||||
| Opening balance as of 1 January 2024 | - | (5,298) | (6,915,741) | (22,481) | (2,729,810) | (5,410,260) | (5,857,834) | - | (20,941,424) |
| Charge for the period (*) | - | (72) | (153,925) | (157) | (55,507) | (30,993) | (194,003) | - | (434,656) |
| Disposals | - | - | - | - | 8 | - | - | - | 8 |
| Closing balance as of 31 March 2024 | - | (5,370) | (7,069,666) | (22,638) | (2,785,309) | (5,441,253) | (6,051,837) | - | (21,376,073) |
| Carrying value as of 31 March 2024 | 229,798 | 9,989 | 2,167,685 | 2,571 | 512,939 | 97,344 | 2,869,377 | 105,253 | 5,994,957 |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Licenses | Rights | Other | Total | |
|---|---|---|---|---|
| Cost | ||||
| Opening balance as of 1 January 2025 | 8,808,265 | 2,056,296 | - | 10,864,561 |
| Additions | - | 46,101 | - | 46,101 |
| Closing balance as of 31 March 2025 | 8,808,265 | 2,102,397 | - | 10,910,662 |
| Accumulated amortization | ||||
| Opening balance as of 1 January 2025 | - | (1,557,157) | (1,557,157) | |
| Charge for the period | - | (23,660) | - | (23,660) |
| Closing balance as of 31 March 2025 | - | (1,580,817) | - | (1,580,817) |
| Carrying value as of 31 March 2025 | 8,808,265 | 521,580 | - | 9,329,845 |
| Licenses | Rights | Other | Total | |
|---|---|---|---|---|
| Cost | ||||
| Opening balance as of 1 January 2024 | 5,844,366 | 1,939,440 | 465 | 7,784,271 |
| Additions | - | 2,827 | - | 2,827 |
| Closing balance as of 31 March 2024 | 5,844,366 | 1,942,267 | 465 | 7,787,098 |
| Accumulated amortization | ||||
| Opening balance as of 1 January 2024 | - | (1,458,798) | (465) | (1,459,263) |
| Charge for the period | - | (25,733) | - | (25,733) |
| Closing balance as of 31 March 2024 | - | (1,484,531) | (465) | (1,484,996) |
| Carrying value as of 31 March 2024 | 5,844,366 | 457,736 | - | 6,302,102 |
| Hospital Buildings | Total | |
|---|---|---|
| Cost | ||
| 1 January 2025 | 13,839,418 | 13,839,418 |
| Additions | 1,889,012 | 1,889,012 |
| Charge of the period (*) | (290,279) | (290,279) |
| 31 March 2025 | 15,438,151 | 15,438,151 |
(*) For the period ended March 31, 2025, right of use assets depreciation expenses of TRY 287,551 has been charged to 'cost of service' (1 January – 31 March 2024: TRY 374,837), TRY 2,728 to 'general administrative and marketing expenses (1 January – 31 March 2024: TRY 3,000).
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Hospital Buildings | Total | |
|---|---|---|
| Cost | ||
| 1 January 2024 | 11,507,188 | 11,507,188 |
| Additions | 2,115,189 | 2,115,189 |
| Charge of the period | (377,837) | (377,837) |
| 31 March 2024 | 13,244,540 | 13,244,540 |
Payables for employment benefits:
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Fees payable to doctors and other personnel | 506,984 | 414,532 |
| Social security premiums payable | 381,236 | 158,941 |
| 888,220 | 573,473 |
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Unused vacation provision | 185,971 | 150,380 |
| 185,971 | 150,380 |
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Unused vacation provision | 134,588 | 106,268 |
| Retirement pay provision | 130,063 | 117,845 |
| 264,651 | 224,113 |
Other Current Asset
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| VAT carried forward | 321,747 | 374,016 |
| Other miscellaneous current assets | 78,785 | 51,533 |
| 400,532 | 425,549 |
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Litigation provisions | 47,990 | 45,236 |
| Social Security discounts provisions | 48,381 | 53,475 |
| 96,371 | 98,711 |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Total TRY | ||||
|---|---|---|---|---|
| 31 March 2025 | Equivalent | TL | USD | EUR |
| A.CPM given on behalf of its own legal entity | ||||
| - Collateral | 1,974,447 | 1,839,933 | 156 | 3,160 |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| B. CPM given on behalf of the subsidiaries included in full consolidation | ||||
| (*) | -- | -- | -- | -- |
| - Collateral | 218,376 | 218,376 | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| C. CPM given for execution of ordinary commercial activities to collect | ||||
| third parties debt | -- | -- | -- | -- |
| - Collateral | -- | -- | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| D. Total amount of other CPM given | -- | -- | -- | -- |
| i. Total Amount of CPM on behalf of the main partner | -- | -- | -- | -- |
| - Collateral | -- | -- | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| ii. Total amount of CPM given on behalf of other Company companies | ||||
| that do not cover B and C | -- | -- | -- | -- |
| - Collateral | -- | -- | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| iii. Total amount of CPM on behalf of third parties that do not cover C | -- | -- | -- | -- |
| - Collateral | -- | -- | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| Total | 2,192,823 | 2,058,309 | 156 | 3,160 |
(*) The Group has given guarantees amounting to TRY 320,511 related to the loans in Note 5 for the companies under full consolidation.
Guarantees given generally include letters of guarantee received from banks to be given to institutions and suppliers.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Toplam TL | ABD | |||
|---|---|---|---|---|
| 31 December 2024 | karşılığı | TL | Doları | Avro |
| A.CPM given on behalf of its own legal entity | ||||
| - Collateral | 1,702,750 | 1,568,325 | 171 | 3,160 |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| B. CPM given on behalf of the subsidiaries included in full consolidation | ||||
| (*) | -- | -- | -- | -- |
| - Collateral | 191,958 | 191,958 | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| C. CPM given for execution of ordinary commercial activities to collect | ||||
| third parties debt | -- | -- | -- | -- |
| - Collateral | -- | -- | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| D. Total amount of other CPM given | -- | -- | -- | -- |
| i. Total Amount of CPM on behalf of the main partner | -- | -- | -- | -- |
| - Collateral | -- | -- | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| ii. Total amount of CPM given on behalf of other Company companies | ||||
| that do not cover B and C | -- | -- | -- | -- |
| - Collateral | -- | -- | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| iii. Total amount of CPM on behalf of third parties that do not cover C | -- | -- | -- | -- |
| - Collateral | -- | -- | -- | -- |
| - Pledge | -- | -- | -- | -- |
| - Mortgage | -- | -- | -- | -- |
| Total | 1,894,708 | 1,760,283 | 171 | 3,160 |
(*) The Group has given guarantees amounting to TRY 481,058 related to the loans in Note 5 for the companies under full consolidation.
Guarantees given generally include letters of guarantee received from banks to be given to institutions and suppliers.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Shareholders | % | 31 March 2025 | % | 31 December 2024 |
|---|---|---|---|---|
| Lightyear Healthcare B.V. | 37.76% | 72,131 | 37.76% | 72,131 |
| Sancak İnşaat Turizm Nakliyat ve Dış Ticaret A.Ş. | 16.72% | 31,943 | 16.72% | 31,943 |
| Muharrem Usta | 9.78% | 18,678 | 9.78% | 18,678 |
| Adem Elbaşı | 3.26% | 6,226 | 3.26% | 6,226 |
| İzzet Usta | 1.30% | 2,490 | 1.30% | 2,490 |
| Saliha Usta | 0.98% | 1,868 | 0.98% | 1,868 |
| Nurgül Dürüstkan Elbaşı | 0.98% | 1,868 | 0.98% | 1,868 |
| Halka Açık Kısım | 29.22% | 55,808 | 29.22% | 55,808 |
| 100.00% | 191,012 | 100.00% | 191,012 |
As of March 31, 2025 the total number of ordinary shares is 191,012 thousand shares (2024: 191,012 thousand shares) with a par value of TRY 1 per share (2024: TRY 1 per share).
The share capital is divided into 191,012 thousand shares (December 31, 2024: 191,012 thousand shares), with 88,229 thousand A type shares and 102,783 thousand B type shares.
In accordance with the Capital Markets Board's (the "CMB") Resolution No: 21/655 issued on July 23, 2010, it is regarded that 26.71% of the shares are in circulaton in accordance with CSD as of March 31, 2025 (Note 1). Shares in circulation rate is 26.71% as of April 1, 2025.
On February 7, 2018, the Group launched initial public offering ("IPO") of 72,834 thousand B type bearer shares corresponding to 35.01% of total shares. From the initial public offering, TRY600,000 was generated to the Group. After the IPO related expenses amounting to TRY12,259 were deducted from proceeds, out of TRY587,741, share capital increase was made with the amount of TRY31,579 and the remaning amount was used in the share premium increase by TRY556,162.
The related amount became 4,204,499 TRY after applying inflation accounting.
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Share premiums | 4,204,499 | 4,204,499 |
| 4,204,499 | 4,204,499 |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
The legal reserves consist of first and second legal reserves, appropriated in accordance with the Turkish Commercial Code. The first legal reserve is appropriated out of historical statutory profits at the rate of 5% per annum, until the total reserve reaches 20% of the historical paid-in share capital. The second legal reserve is appropriated after the first legal reserve and dividends, at the rate of 10% per annum of all cash dividend distributions.
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Legal reserves | 6,030 | 6,920 |
| Restricted reserves appropriated from profit | 98,161 | 97,271 |
| 104,191 | 104,191 |
| Revenue | 1 January-31 March 2025 |
1 January-31 March 2024 |
|---|---|---|
| Hospital services (*) | 11,754,257 | 10,993,413 |
| 11,754,257 | 10,993,413 |
(*) Hospital services includes foreign medical revenue and other income.
| 1 January-31 | 1 January-31 | |
|---|---|---|
| Cost of services | March 2024 | March 2025 |
| Material consumption | (1,417,567) | (1,564,222) |
| Doctor expenses | (3,084,632) | (2,653,763) |
| Personnel expenses | (2,145,391) | (1,873,965) |
| Depreciation and amortization expenses (Note 10,11) | (746,365) | (779,432) |
| Services rendered by third parties | (257,988) | (594,618) |
| Rent expenses | (295,662) | (40,843) |
| Other (*) | (574,230) | (620,154) |
| (8,521,835) | (8,126,997) |
(*) Other expenses mainly comprise expenses incurred for electricity, water and natural gas.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| 1 January-31 | 1 January-31 | |
|---|---|---|
| General administrative expenses | March 2024 | March 2025 |
| Personnel expenses | (618,233) | (435,824) |
| Sponsorship and advertising expenses (*) | (231,888) | (290,707) |
| Depreciation and amortization expenses (Note 10,11) | (42,865) | (58,794) |
| Outsourcing expenses | (59,265) | (41,702) |
| Rent expenses | (16,912) | (12,363) |
| Taxes and duties | (3,999) | (3,352) |
| Bad debt allowance (Note 6) | (4,332) | (13,623) |
| Representation and entertainment expenses | (998) | (1,043) |
| Maintenance expenses | (3,663) | (2,193) |
| Service expenses | (1,022) | (1,138) |
| Communication expenses | (6,874) | (5,948) |
| Lawsuit provision | (6,890) | (16,720) |
| Other | (80,813) | (12,466) |
| (1,077,754) | (895,873) |
(*) Sponsorship and advertising expenses includes marketing expenses related to the income of domestic and foreing medical tourism.
| Other income from operating activities | 1 January-31 March 2025 |
1 January-31 March 2024 |
|---|---|---|
| Foreign exchange gains from operations | 458,482 | 291,586 |
| Trade payables discount | (598) | 64,127 |
| Other income | 60,376 | 41,777 |
| 518,260 | 397,490 |
| 1 January-31 | 1 January-31 | |
|---|---|---|
| Other expenses from operating activities | March 2025 | March 2024 |
| Foreign exchange losses from operations | (183,813) | (224,058) |
| Trade receivables discount | (4,595) | (31,040) |
| SSI return expenses | (19,246) | (15,962) |
| Other expenses | (208,355) | (109,917) |
| (416,009) | (380,977) |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Income from investment activities | 1 January-31 March 2025 |
1 January-31 March 2024 |
|---|---|---|
| Gain on sale of fixed assets | 222 | 298 |
| 222 | 298 |
| 1 January-31 | 1 January-31 | |
|---|---|---|
| Expenses from investment activities | March 2025 | March 2024 |
| Loss on sale of fixed assets | (2,094) | -- |
| (2,094) | -- |
| 1 January-31 March 2025 |
1 January-31 March 2024 |
|
|---|---|---|
| Interest expenses from bank borrowings | (243,196) | (332,815) |
| Interest expenses from financial lease obligations | (1,897) | (3,509) |
| Interest expenses from bonds issued | (132,924) | (215,467) |
| Bank commissions | (158,591) | (135,459) |
| Interest expenses from lease liabilities (*) | (379,035) | (234,707) |
| Other interest expenses | (104,907) | (61,231) |
| Total interest expenses | (1,020,550) | (983,188) |
| Interest expenses from lease liabilities (*) | (9,061) | (12,218) |
| Net foreign exchange loss | (158,725) | (666) |
| Total financial expenses | (1,188,336) | (996,072) |
| Interest income | 234,476 | 172,390 |
| Finance expenses, net | (953,860) | (823,682) |
(*) Consists of interest expense and foreign exchange loss related to the lease liabilities under TFRS 16.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
(669,431) (1,766,428)
| Statement of financial position items | |
|---|---|
| Inventories | (16,517) |
| Prepaid expenses (Short term) | 6,596 |
| Property, plant and equipment | 556,005 |
| Intangible assets | 339,507 |
| Right of use assets | 485,232 |
| Prepaid expenses (Long term) | 126,822 |
| Deferred tax liability | 292,309 |
| Deferred income | (48,240) |
| Share capital | (19,221) |
| Share premium | (55,965) |
| Treasury shares | 61,045 |
| Other comprehensive income or expenses that will not be reclassified | 39,802 |
| Restricted reserves | (1,248) |
| Accumulated income/loses | (1,404,391) |
| Statement of profit or loss items | |
| Revenue | (287,843) |
| Cost of sales | 515,415 |
| General administrative expenses | 46,600 |
| Other income from operating activities | (12,941) |
| Other expenses from operating activities (-) | 8,860 |
| Finance expenses | 12,166 |
| Income from investing activities | (82) |
| NET MONETARY POSITION GAINS/(LOSSES) | 643,911 |
| Short term payables due to current tax | 31 March 2025 | 31 March 2024 |
|---|---|---|
| Current period tax liabilities | 741,474 | 379,958 |
| 741,474 | 379,958 | |
| Current tax liabilities | 31 March 2025 | 31 March 2024 |
| Current corporate tax provision | 1,329,102 | 1,026,718 |
| Less: Prepaid taxes and funds | (587,628) | (646,760) |
| 741,474 | 379,958 | |
| 1 January -31 | 1 January -31 | |
| Tax (expense)/income | March 2025 | March 2024 |
| Current tax income | (396,110) | (239,987) |
| Deffered tax income/(expense) | (273,321) | (1,526,441) |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
The Group is subject to Turkish corporate taxes in force. The necessary provisions are allocated in the consolidated financial statements for the estimated liabilities based on the Group's results for the year. Turkish tax legislation does not permit a parent company and its subsidiary to file a consolidated tax return. Therefore, provisions for taxes, as reflected in the consolidated financial statements, have been calculated on a separate-entity basis.
Corporate tax is applied on taxable corporate income, which is calculated from the statutory accounting profit by adding non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized.
The advance corporate income tax rate is 25% in 2025 (2024 25%).
In Turkey, provisional tax is calculated and accrued on a quarterly basis. The provisional tax rate to be calculated on corporate earnings during the taxation phase of 2025 corporate earnings as of temporary tax periods is 25% (2024: 25%). Losses can be carried forward for a maximum of 5 years, to be deducted from the taxable profits that will arise in future years. However, the losses incurred cannot be deducted retrospectively from the profits of previous years.
The Group recognizes deferred tax assets and liabilities based upon temporary differences arising between its financial statements as reported for TFRS purposes and its statutory tax financial statements. These differences usually result in the recognition of revenue and expenses in different reporting periods for TFRS and tax purposes and they are given below. As of 31 March 2025, tax rate used in the calculation of deferred tax assets and liabilities was 25% over temporary timing differences (31 December 2024: 25%) In Turkey, the companies cannot declare a consolidated tax return, therefore subsidiaries that have deferred tax assets position were not netted off against subsidiaries that have deferred tax liabilities position and disclosed separately.
The Group has various investment incentive certificates that were signed by the Turkish Ministry of Economy and approved by General Directorate of Incentive Implementation and Foreign Capital. With those incentives, the Group is eligible for a corporate tax deduction rate ranging between 40%- 80% for an unlimited time, which amounts to a total deferred tax asset of TRY 985,288 (December 31, 2024: TRY 1,060,503). Respective deferred tax asset was calculated to be 15%- 40% of total investment contribution with regards to the respective investment incentive certificates. Additionally, the Group is entitled to social security premium support from the Turkish Ministry of Economy, related to the hospitals that have completed their greenfield investments
As of March 31, 2025, the Group has tax loss amounting to TRY 318,354 (December 31, 2024: TRY 152,755). TRY 79,589 (December 31, 2024: TRY 38,188) deferred tax assets have been recorded concerning this loss.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| Defered tax assets/ (liabilities) | 31 March 2025 | 31 December 2024 |
|---|---|---|
| Tax losses carried forward | 79,589 | 38,188 |
| Depreciation differences of tangible and intangible assets | (2,903,618) | (2,647,035) |
| Provision for employment termination benefits | 35,258 | 35,790 |
| Vacation pay liability | 80,140 | 64,152 |
| Temporary difference between the tax base and carrying amount of | - | - |
| financial liabilities | (58,904) | (59,046) |
| Tax advantage from investment incentive | 985,288 | 1,060,503 |
| Right of use asset | (2,314,287) | (2,208,503) |
| Other | 448,747 | 361,033 |
| (3,647,787) | (3,354,918) | |
| Deferred tax asset | 2,627,581 | 2,683,879 |
| Deferred tax liability | (6,275,368) | (6,038,797) |
| (3,647,787) | (3,354,918) |
Tax losses carried forward and their expiry dates are as follows:
| 31 March 2025 | 31 December 2024 | |
|---|---|---|
| Losses carried | ||
| forward for wich | Losses carried forward | |
| deferred tax assests | for wich deferred tax | |
| Expiration schedule of carryforward tax losses | recognized | assests recognized |
| Expiring in 2025 | 1,264 | 2,769 |
| Expiring in 2026 | 260 | 1,391 |
| Expiring in 2027 | 18,796 | 287 |
| Expiring in 2028 | 130,402 | 20,687 |
| Expiring in 2029 | 167,632 | 127,621 |
| 318,354 | 152,755 |
Movement of deferred tax (assets)/liabilities for the period ended March 31, 2025 and March 31, 2024 are as follows:
| 1 January-31 | 1 January-31 | |
|---|---|---|
| Movement of deffered tax liabilities | March 2025 | March 2024 |
| Opening balance as of January 1 | (3,354,918) | (2,247,898) |
| Charged to profit or loss | (273,321) | (1,526,441) |
| Charged to equity | (19,548) | 10,510 |
| (3,647,787) | (3,763,829) |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
The reconciliation of the current tax expense and net income for the period is as follows:
| Reconcilation of tax provision: | 1 January-31 March 2025 |
1 January-31 March 2024 |
|---|---|---|
| Loss before tax | 1,945,098 | 2,804,867 |
| Tax at the domestic income tax rate of 25% (2024: 25%) | (486,275) | (701,217) |
| Tax effects of | ||
| - Expenses that are not deductible in determining taxable profit | (64,490) | (26,128) |
| - Effect of tax advantage from investment incentive | 21,744 | 55,985 |
| - Reduced corporate tax effect | 79,811 | 90,410 |
| - Monetary gain loss effect | (160,978) | (1,128,170) |
| - Other | (59,243) | (57,308) |
| Income tax income recognised in profit or loss | (669,431) | (1,766,428) |
The weighted average number of shares and earnings per share is as follows:
| 1 January-31 | 1 January-31 | |
|---|---|---|
| March 2025 | March 2024 | |
| Weighted average number of shares | 191,012 | 208,037 |
| Net gain/(loss) for the period for the equity holders of the parent | 1,169,766 | 943,233 |
| Earnings/(loss) per share for equity holder of the parent | 6,12 | 4,53 |
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
Foreign currency risk management
Transactions in foreign currencies expose the Company to foreign currency risk. Exchange rate exposures are managed within approved policy parameters utilising forward foreign exchange contracts. The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities at the reporting date are as follows:
| TL | |||||
|---|---|---|---|---|---|
| Equivalents (Functional |
|||||
| 31 March 2025 | currency) | USD | EUR | GBP | Other |
| 1. Trade receivables | 266,586 | 2,943 | 3,037 | 652 | - |
| 2a. Monetary financial assets | 1,534,700 | 11,330 | 26,300 | 745 | - |
| 2b. Non monetary financial assets | 301,841 | 2,520 | 5,074 | 3 | - |
| 3. Other | 24,524 | 9 | 66 | 441 | - |
| 4. Current Assets | 2,127,651 | 16,802 | 34,476 | 1,841 | - |
| 5. Trade receivables | - | - | - | - | - |
| 6a. Monetary financial assets | - | - | - | - | - |
| 6b. Non monetary financial assets | - | - | - | - | - |
| 7. Other | 924,869 | 11,489 | 11,520 | - | 1,000 |
| 8. Non-current assets | 924,869 | 11,489 | 11,520 | - | 1,000 |
| 3,052,520 | 28,291 | 45,997 | 1,841 | 1,000 | |
| 9. Total assets | |||||
| 10. Trade Payables | (192,238) | (149) | (4,584) | - | - |
| 11a. Financial liabilities (leasing) | (282,471) | - | (6,940) | - | - |
| 11b. Financial liabilities (leasing) | (24,044) | - | (591) | - | - |
| 11c. Lease Liabilities | (43,714) | (1,074) | - | - | |
| 12a. Other monetary liabilities | (202,567) | (2,565) | (2,563) | (29) | - |
| 13. CURRENT LIABILITIES | (745,034) | (2,714) | (15,752) | (29) | - |
| 14.Trade Payables | - | - | - | - | - |
| 15a. Financial liabilities (leasing) | (1,776,083) | - | (43,636) | - | - |
| 15b. Financial liabilities (leasing) | - | - | - | - | - |
| 15c. Lease Liabilities | (74,240) | - | (1,824) | - | - |
| 16a. Other monetary liabilities | (638,153) | (16,898) | - | - | - |
| 16b. Other non-monetary liabilities | - | - | - | - | - |
| 17. LONG TERM LIABILITIES | (2,488,476) | (16,898) | (45,460) | - | - |
| 18. TOTAL LIABILITIES | (3,233,510) | (19,612) | (61,212) | (29) | - |
| 20. NET FOREIGN CURRENCY ASSET LIABILITY (9+8+19) |
(180,997) | 8,680 | (15,215) | 1,812 | 1,000 |
| 21. MONETARY ITEMS NET FOREIGN CURRENCY ASSET/LIABILITY POSITION |
(1,432,223) | (5,339) | (31,875) | 1,368 | - |
(1+2a+10+11a+11b+11c+12a+14+15+16a)
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| TL Equivalents | |||||
|---|---|---|---|---|---|
| 31 December 2024 | (Functional currency) |
USD | EUR | GBP | Other |
| 1. Trade receivables | 719,081 | 8,579 | 8,810 | 620 | - |
| 2a. Monetary financial assets | 1,108,027 | 24,688 | 2,856 | 728 | - |
| 2b. Non monetary financial assets | 61,699 | 48 | 1,476 | 3 | - |
| 3. Other | 2,441 | 26 | 34 | 1 | - |
| 4. Current Assets | 1,891,248 | 33,341 | 13,176 | 1,352 | - |
| 5. Trade receivables | - | - | - | - | - |
| 6a. Monetary financial assets | - | - | - | - | - |
| 6b. Non monetary financial assets | - | - | - | - | - |
| 7. Other | 800,318 | 9,789 | 9,845 | - | 1,000 |
| 8. Non-current assets | 800,318 | 9,789 | 9,845 | - | 1,000 |
| 9. Total assets | 2,691,566 | 43,130 | 23,021 | 1,352 | 1,000 |
| 10. Trade Payables | (80,913) | (1,387) | (670) | (1) | - |
| 11a. Financial liabilities (leasing) | - | - | - | - | - |
| 11b. Financial liabilities (leasing) | (25,033) | - | (619) | - | - |
| 11c. Lease Liabilities | (43,663) | - | (1,080) | - | - |
| 12a. Other monetary liabilities | (482,131) | (4,956) | (7,102) | (57) | - |
| 13. CURRENT LIABILITIES | (631,740) | (6,343) | (9,471) | (58) | - |
| 14.Trade Payables | - | - | - | - | - |
| 15a. Financial liabilities (leasing) | - | - | - | - | - |
| 15b. Financial liabilities (leasing) | - | - | - | - | - |
| 15c. Lease Liabilities | (85,248) | - | (2,108) | - | - |
| 16a. Other monetary liabilities | (641,775) | (16,554) | - | - | - |
| 16b. Other non-monetary liabilities | - | - | - | - | - |
| 17. LONG TERM LIABILITIES | (727,023) | (16,554) | (2,108) | - | - |
| 18. TOTAL LIABILITIES | (1,358,764) | (22,898) | (11,579) | (58) | - |
| 20. NET FOREIGN CURRENCY ASSET LIABILITY (9+8+19) | 1,332,802 | 20,232 | 11,442 | 1,294 | 1,000 |
| 21. MONETARY ITEMS NET FOREIGN CURRENCY | |||||
| ASSET/LIABILITY POSITION | 1,109,488 | 26,924 | 87 | 1,290 | - |
| (1+2a+10+11a+11b+11c+12a+14+15+16a) |
The Group is exposed to foreign exchange risk arising primarily from USD and EUR.
The following table details the Group's sensitivity to a 20% increase and decrease against the relevant foreign currencies. 20% is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 20% change in foreign currency rates. The sensitivity analysis includes external loans as well as loans to foreign operations within the Group where the denomination of the loan is in a currency other than the currency of the lender or the borrower. A positive number below indicates an increase in profit before tax.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
| 31 March 2025 | |||
|---|---|---|---|
| Profit / (Loss) | |||
| Valuation of foreign currency |
Devaluation of foreign currency |
||
| In the case of US dollar gaining 20% value against TRY | |||
| 1- USD net asset/liability | 65,563 | (65,563) | |
| 2- Portion hedged against USD risk (-) | - | - | |
| 3- USD net effect (1 +2) | (65,563) | 65,563 | |
| In the case of EUR gaining 20% value against TRY | |||
| 4 -EUR net asset/liability | (104,789) | 104,789 | |
| 5 - Portion hedged against EUR risk (-) | - | - | |
| 6- EUR net effect (4+5) | (104,789) | 104,789 | |
| In the case of GBP gaining 20% value against TRY | |||
| 7- Other currency net asset/liabilitit | 17,685 | (17,685) | |
| 8 - Portion hedged against other currency risk (-) | - | - | |
| 9- Other currency net effect (7+8) | 17,685 | (17,685) | |
| TOTAL (3+6) | (21,541) | 21,541 |
| 31 December 2024 | |||
|---|---|---|---|
| Profit / (Loss) | |||
| Valuation of | Devaluation of | ||
| foreign currency | foreign currency | ||
| In the case of US dollar gaining 20% value against TRY | |||
| 1- USD net asset/liability | 156,872 | (156,872) | |
| 2- Portion hedged against USD risk (-) | - | - | |
| 3- USD net effect (1 +2) | 156,872 | (156,872) | |
| In the case of EUR gaining 20% value against TRY | |||
| 4 -EUR net asset/liability | 92,546 | (92,546) | |
| 5 - Portion hedged against EUR risk (-) | - | - | |
| 6- EUR net effect (4+5) | 92,546 | (92,546) | |
| In the case of GBP gaining 20% value against TRY | |||
| 7- Other currency net asset/liabilitit | 12,607 | (12,607) | |
| 8 - Portion hedged against other currency risk (-) | - | - | |
| 9- Other currency net effect (7+8) | 12,607 | (12,607) | |
| TOTAL (3+6) | 249,419 | (249,419) |
None.
(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)
Interest, Tax, Depreciation and Amortization ("EBITDA") is calculated by the Group Management with the addition of the period's depreciation and amortization, financial income and expenses, other adjustments and tax deductions to net loss before tax.
The EBITDA calculation movements for the period ended March 31, 2025 and March 31, 2024 are as follows:
| 31 March | 31 March | |
|---|---|---|
| EBITDA CALCULATION | 2025 | 2024 |
| i. Net loss before tax |
1,945,098 | 2,804,867 |
| ii. Depreciation and amortization of tangible and intangible fixed assets including |
789,230 | 838,228 |
| non-cash provisions related to assets such as goodwill | ||
| iii. Total net finance expenses, net of interest income |
786,074 | 810,798 |
| iv. Fx gains/losses, net under finance expenses |
167,786 | 12,884 |
| v. Fair value differences of derivative instruments |
- | - |
| vi. Extraordinary (income)/expenses |
67,773 | 142,419 |
| vii. Rediscount income/expense (net imputed interest) |
5,193 | (33,087) |
| viii. Gain on bargain purchase price |
- | - |
| ix. Legal case provision expenditures which are reflected to financial statements by |
(6,890) | 16,720 |
| general accounting principles | ||
| x. Unused vacation pay provision expenses which are reflected to financial |
63,911 | 78,797 |
| statements by the general accounting principles | ||
| xi. Retirement pay provision expenses which are reflected to financial statements |
12,218 | 9,231 |
| by the general accounting principles | ||
| xii. Doubtful receivables provision expenses which are reflected to financial |
4,332 | 13,623 |
| statements by the general accounting principles | ||
| xiii. Non-cash sale and lease back expenses which are reflected to financial |
- | 282 |
| statements by the general accounting principles | ||
| xiv. (Income)/expenses from investment operations | 1,872 | (298) |
| xv. Monetary gain / (loss) |
(643,911) | (1,641,195) |
| EBIDTA | 3,192,686 | 3,053,269 |
| TFRS 16 Lease payment effect | (544,998) | (428,902) |
| Adjusted EBITDA | 2,647,688 | 2,624,367 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.